Post Procedural Pain Following Intercostal Nerve Block For Right-Sided Percutaneous Transhepatic Biliary Catheter Placement
Matthew Krosin, MD
Primary Investigator
Brief description of study
Detailed description of study
What will happen during the study?
Single-blind, randomized control trial comparing the addition of an intercostal methylprednisolone and bupivacaine nerve block + standard of care vs. sham nerve block + standard of care for postprocedural pain following initial right-sided PTBD placement. The primary outcome measure will be post-procedural pain, as assessed by VAS. VAS will be administered with predetermined verbiage each time to reduce potential bias. Following initial catheter placement, all VAS will be administered by a blinded proceduralist during catheter exchange/upsize. This intervention will not affect management of the participant’s biliary stricture.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Central and peripheral benign biliary strictures
-
Age: 18 years - 100 years
-
Gender: All
Inclusion Criteria
Adults ≥ 18 years
Patients with central and peripheral benign biliary strictures presenting for first time right-sided intercostal biliary catheter placement
Exclusion Criteria
Patients with malignant biliary strictures
Patients requiring subcostal drain placement
Patients with allergies to Bupivacaine and/or Methylprednisolone
Patients unable to reliably return for clinic appointments or telehealth visits
Patients with chronic, uncontrolled pain
Patients with preexisting neuropathy
Patients with diabetes and ocular complications
Patients with prior major thoracic surgery
Patients who are pregnant or are planning to become pregnant
Patients who cannot consent for themselves.